期刊文献+

他汀类药物在心房颤动治疗中的作用分析 被引量:5

Analysis of the role of statin drugs in the treatment of atrial fibrillation
下载PDF
导出
摘要 目的 观察他汀类药物在心房颤动治疗中的作用.方法 将2008年1月至2011年1月阿拉善盟中心医院收治的86例持续性心房颤动患者完全随机分为他汀组和对照组,各43例.给予体外同步直流电复律后2组均给予胺碘酮200 mg、3次/d口服,1周后改为200 mg、2次/d,再1周后改为200 mg、1次/d维持;他汀组同时给予辛伐他汀20 mg,每晚1次口服.患者复律前后均给予华法林钠正规抗凝治疗,共治疗6个月.患者恢复窦性心律后1、2周及以后每4周分别行心电图和动态心电图检查.结果 他汀组维持窦性心律38例(88.4%),未维持窦性心律5例(11.6%);对照组维持窦性心律29例(67.4%),未维持窦性心律14例(32.6%).他汀组维持窦性心律的比例明显高于对照组(P<0.05).结论 他汀类药物在预防心房颤动复发上有应用价值. Objective To detect the role of statin drugs in the treatment of atrial fibrillation.Methods Totally 86 cases with atrial fibrillation were collected between January 2008 and January 2011.The patients were randomly divided into two groups.After being given in vitro synchronous dc after cardioerter,both groups had amiodarone 200 mg (200 mg/piece) with 3 times a day,200 mg with 2 times a day after one week,and 200 mg once a day for a long term.Statin group also had simvastatin 20 mg (20 mg/piece) every night.All patients were given warfarin sodium fomal anticoagulant therapy before and after cardioerter.Total treatment was for 6 months.Results The statin group showed sinus rhythm in 38 cases (88.4%) ; the control group showed sinus rhythm in 29 cases (67.4%).The proportion of sinus rhythm in simvastatin group was significantly higher than that in the control group (88.4% vs 67.4%,P〈0.05).Conclusion Statins can prevent recurrence of atrial fibrillation.
出处 《中国医药》 2013年第8期1043-1044,共2页 China Medicine
关键词 心房颤动 他汀类药物 辛伐他汀 Atrial fibrillation Statins drug Simvastatin
  • 相关文献

参考文献9

  • 1Adam O, Neuberger HR, Bfihm M, et al. Prevention of atrial fi- brillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase in- hibitors. Circulation, 2008,118(12) : 1285-1293.
  • 2易欣,黎明江.胺碘酮联合辛伐他汀与单用胺碘酮治疗心房颤动的Meta分析[J].临床误诊误治,2012,25(5):66-71. 被引量:6
  • 3Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharma- col Toxicol, 2005,45:89-118.
  • 4Shiroshita-Takeshita A, Brundel B J, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electro- physiol, 2005,13 (3) : 181-193.
  • 5梁海雁,姚传臣,骈晶.瑞舒伐他汀对心房颤动患者转复后C反应蛋白的影响[J].临床荟萃,2012,27(5):433-434. 被引量:6
  • 6Ganotakis ES, Mikhailidis DP, Vardas PE. Atrial fibrillation, in- flammation and statins. Hellenic J Cardiol, 2006,47(2) :51-53.
  • 7Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase in- hibitor atorvastatin prevents atrial fibrillation by inhibiting inflam- mation in a canine sterile peficardifis model. Cardiovasc Res, 2004,62( 1 ) :105-111.
  • 8商丽华,胡大一,赵秀丽,张仁汉.普伐他汀对快速起搏心房肌结构重构的影响[J].中华心律失常学杂志,2004,8(3):172-176. 被引量:21
  • 9Skalidis EI, Zacharis EA, Tsetis DK, et al. Endothelial cell func- tion during atrial fibrillation and after restoration of sinus rhythm. Am J Cardiol, 2007,99 (9) : 1258-1262.

二级参考文献29

共引文献29

同被引文献81

  • 1王少黎,费丽萍,郭艳霞.C-反应蛋白在老年性房颤的动态变化观察[J].长治医学院学报,2007,21(2):114-115. 被引量:3
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5222
  • 3王静,孙建勋,王宏运.内科学.2版.郑州:郑州大学出版社,2009:821-828.
  • 4Jabre P,Jouven X,Adent F,et al.Atrial fibrillation and death aftermyocardial infarction:a community study[J].Circulation,2011(19):2094-2100.
  • 5Wann LS,Curtis AB,January CT,et al.2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation(updating the 2006 guideline):A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Circulation,2011(123):104-123.
  • 6Schmitt J,Duray G,Gersh BJ,et al.Atrial fibrillation in acute myocardial infarction:a systematic review of the incidence,clinical features and prognostic implications[J].Eur Heart J,2009(30):1038-1045.
  • 7Han Z,Yanmin Y,Jun Z,et al.Prognostic value of admission heart rate in patients with ST-segment elevation myocardial infarction:Role of Type 2 diabetes mellitus[J].BMC cardiovascular disorders,2012(1):104-107.
  • 8Cortes-Bergoderi M,Pineda AM,Santana O.The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductaseinhibitors in gastrointestinal tract disorders:a comprehensive review[J].J Gastrointestin Liver Dis,2013,22(2):199-204.
  • 9Hodis HN,Mack WJ.The timing hypothesis and hormone replacement therapy:a paradigm shift in the primary prevention of coronary heart disease in women[J].J Am Geriatr Soc,2013,61(6):1011-1018.
  • 10Asanin M,Stankovic S,Mrdovic I,et al.B-type natriuretic peptide predicts new-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention[J].Peptides,2012(1):74-77.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部